Treating uveitis aims to prevent the development of ocular structural changes related to intraocular inflammation that otherwise could lead to vision loss. Inflammation control is achieved with immunosuppressive drugs, primarily corticosteroids, and for many years has relied on these, particularly in cases with concomitant systemic diseases or bilateral uveitis. Although these drugs are effective in controlling the inflammation, many patients do not have systemic involvement and are not keen to undertake systemic treatment.

Direct access to the intraocular space means the eye is an ideal organ for local therapy, achieving high drug concentration on target. Local therapeutic options for the management of sight-threatening noninfectious uveitis (NIU) include corticosteroids, methotrexate, antievascular endothelial growth factor (VEGF), and more recently, intravitreal biologics. The increased ability of these agents to sustain inflammatory control, although requiring repeat drug administrations, can help to reduce the dose of systemic immunosuppression while maintaining a state of no inflammation and preserving vision in such vision-threatening conditions.